Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Effectiveness and safety of polatuzumab vedotin combined with zuberitamab plus cyclophosphamide, doxorubicin and prednisone in untreated diffuse large B-cell lymphoma: A real-world study from China

View Full Paper
Ask AI
Bookmark
Share

Authors

ZPZhao Peiqi

Discussion

Loading...

Member takes

Overview

Real-world analysis shows pola-Hi-CHP improves complete response rates in high-risk DLBCL, suggesting effective management strategies.

Key Points

  • Pola-Hi-CHP achieved a complete response rate of 83.3% in evaluating untreated diffuse large B-cell lymphoma patients.
  • The International Prognostic Index scores and treatment-emergent adverse events were key features among the study population.
  • Retrospective analysis involved 72 patients, with treatment efficacy and safety evaluated based on the Lugano criteria.
  • Findings suggest the pola-Hi-CHP regimen may effectively address high-risk DLBCL challenges, warranting further studies.

Cite This Study

Zhao Peiqi (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db7ehttps://doi.org/10.1182/blood-2025-2747
View Full Paper
Ask AI
Bookmark
Share